Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths

• Published in: Journal of microbiology, immunology and infection Vol. 53; no. 3; pp. 404 - 412
• Main Authors: Lai, Chih-Cheng, Liu, Yen Hung, Wang, Cheng-Yi, Wang, Ya-Hui, Hsueh, Shun-Chung, Yen, Muh-Yen, Ko, Wen-Chien, Hsueh, Po-Ren
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01.06.2020; Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC; Elsevier
• Subjects: 2019-nCoV; Acute respiratory disease; Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - therapeutic use; Adolescent; Adult; Aged; Alanine - analogs & derivatives; Alanine - therapeutic use; Asymptomatic carrier; Asymptomatic Infections - epidemiology; Betacoronavirus; China - epidemiology; Chloroquine - therapeutic use; Comorbidity; Coronavirus; Coronavirus Infections - epidemiology; Coronavirus Infections - pathology; COVID-19; Humans; Infection Control - methods; Middle Aged; Pandemics - prevention & control; Pneumonia, Viral - epidemiology; Pneumonia, Viral - pathology; SARS-CoV-2; Wuhan pneumonia; Young Adult; China; COVID-19; Wuhan pneumonia; SARS-CoV-2; Coronavirus; 2019-nCoV; Asymptomatic carrier; Acute respiratory disease

Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions,...